Format

Send to

Choose Destination
Regen Med. 2018 Mar;13(2):123-128. doi: 10.2217/rme-2017-0130. Epub 2017 Dec 6.

Lessons for reviewing clinical trials using induced pluripotent stem cells: examining the case of a first-in-human trial for age-related macular degeneration.

Author information

1
Department of Public Policy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
2
Bioethics Section, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.

KEYWORDS:

AMD; age-related macular degeneration; committee meeting minutes; direct benefit; first-in-human trial; iPSC; induced pluripotent stem cell; protecting research participants; reasonable accommodation; review committee; risk assessment; subject selection

PMID:
29210321
DOI:
10.2217/rme-2017-0130
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center